Amendments to the claims:

1. (original) A pharmaceutical composition comprising a per(3,6-anhydro)cyclodextrin, a pharmaceutically effective drug and a carrier.

2. (currently amended) The [C]composition of claim 1, wherein said per(3,6-anhydro)cyclodextrin is selected from the group consisting of hexakis(3,6-anhydro)-α-cyclodextrin, heptakis(3,6-anhydro)-β-cyclodextrin, octakis(3,6-anhydro)-γ-cyclodextrin, and mixtures thereof.

3. (currently amended) The [C]composition of claim 1, wherein said composition is adapted to topical administration.

4. (currently amended) The [C]composition of claim 1, wherein the amount of said peranhydrocyclodextrin is in a range of from 0.01 – 80% by weight of total composition.

5. (currently amended) The [C]composition of claim 1, wherein said composition is adapted to an administration in or around the eye.

6-7. (cancelled)

8. (currently amended) A method of improving drug permeability through a tissue, which method comprises the steps of:
[C]conventionally admixing an effective amount of a per(3,6-anhydro)cyclodextrin, an effective amount of a drug, a carrier, and optionally one or more further ingredients selected from the group of buffers, tonicity enhancing agents, preservatives, solubilizers, stabilizers/solubilizers, and complexing agents; and
administering said pharmaceutical composition comprising said per(3,6-anhydro)cyclodextrin to said tissue.

9. (currently amended) The [M]method of claim 8, wherein said tissue is selected from mucus tissue and ocular tissue[, such as corneal epithelial cells and conjunctival cells].

10. (currently amended) A [M]method of enhancing the bioavailability of a pharmaceutically effective drug, which method comprises conventionally admixing an effective amount of a per(3,6-anhydro)cyclodextrin, an effective amount of a drug, and a carrier.

11. (new claim) The method of claim 9, wherein the mucus tissue is corneal epithelial cells and the ocular tissue is conjunctival cells.